madrid2i

Resumen

[0001] The present invention refers to the medical field. Particularly, the present invention refers to compounds of Formula I or Formula II for use in the treatment of frontotemporal dementia or frontotemporal lobar dementia.

Reivindicaciones

1. Compound characterized by comprising the Formula I, or salts or derivatives thereof, <img class="EMIRef" id="ae850fe2-484b-45fd-b938-6e129c119d50-ib0006" /> wherein, <img class="EMIRef" id="ae850fe2-484b-45fd-b938-6e129c119d50-ib0007" /> represents a double or single bond, X is either C or N, Y is N, O or S, R1 and R1' are independently absent, H, C<1-4> alkyl, or an acyl group COR6; wherein R6 is H or C<1-4> alkyl; and wherein the C<1-4> alkyl comprises cycloalkyl, branched alkyl, alkenyl or alkynyl, optionally substituted with 1-3 halogen atoms, R2, R3, R4, R5, R2' R3', R4' and R5' are independently absent, H, carbonitrile, C<1-4> alkyl, a halogen, aryl, heteroaryl, an alkoxy group OR7, or an amino group NR8R9 ; wherein R7 , R8 and R9 are H or C<1-4> alkyl; and wherein C<1-4> alkyl comprises cycloalkyl, branched alkyl, alkenyl or alkynyl, optionally substituted with 1-3 halogen atoms; for use in the treatment of frontotemporal dementia or frontotemporal lobar dementia. 2. Compound, for use, according to claim 1, characterized in that the compound comprises the Formula II, or salts or derivatives thereof, <img class="EMIRef" id="ae850fe2-484b-45fd-b938-6e129c119d50-ib0008" /> wherein, <img class="EMIRef" id="ae850fe2-484b-45fd-b938-6e129c119d50-ib0009" /> represents a double or single bond, R1 and R1' are independently H or C<1-4> alkyl, wherein the C<1-4> alkyl comprises cycloalkyl, branched alkyl, alkenyl or alkynyl, optionally substituted with 1-3 halogen atoms, R2 and R2' are independently H or an alkoxy group OR7, where R7 is H or C<1-4> alkyl, wherein the C<1-4> alkyl comprises cycloalkyl, branched alkyl, alkenyl or alkynyl, optionally substituted with 1-3 halogen atoms, R3 and R3' are independently H or an alkoxy group OR7, where R7 is H, C<1-4> alkyl, wherein the C<1-4> alkyl comprises cycloalkyl, branched alkyl, alkenyl or alkynyl optionally substituted with 1-3 halogen atoms, a halogen atom or C<1-4> alkyl comprising cycloalkyl, optionally substituted with 1-3 halogen atoms. 3. Compound, for use, according to any of the previous claims, wherein R1 and R1' are both H or prop-2-ynyl, R2 and R2' are both H or methoxy and/or R3 and R3' are both H, methoxy, chloro or trifluoromethyl. 4. Compound, for use, according to any of the previous claims, wherein R1 and R1' are both H, R2 and R2' are both H or methoxy and R3 and R3' are both H, methoxy, chloro or trifluoromethyl. 5. Compound, for use, according to any of the previous claims, wherein R2 and R2' are both H or methoxy and R3 and R3' are both H. 6. Compound, for use, according to any of the previous claims, wherein R3 and R3' are both H, methoxy, chloro or trifluoromethyl and R2 and R2' are both H. 7. Compound, for use, according to any of the previous claims, wherein R1 and R1' are both prop-2-ynyl, R3 and R3' are both methoxy and R2 and R2' are both H. 8. Compound for use, according to any of the previous claims, wherein the compound of Formula I or Formula II is selected from the group comprising: 5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (1) 5,5'-Dimethoxy-1H,1'H-2,3'-biindole (2) 3-(Indolin-2-yl)-1H-indole (3) 5-Chloro-3-(5-chloroindolin-2-yl)-1H-indole (4) 5,5'-Dichloro-1H,1'H-2,3'-biindole (5) 7-Methoxy-3-(7-methoxyindolin-2-yl)-1H-indole (6) 5-(Trifluoromethyl)-3-(5-(trifluoromethyl)indolin-2-yl)-1H-indole (7) 5-Methoxy-3-(5-methoxy-1-(prop-2-yn-1-yl)indolin-2-yl)-1-(prop-2-yn-1-yl)-1H-indole (8) 9. Compound for use, according to any of the previous claims, wherein the compound of Formula I or Formula II is: 5-Methoxy-3-(5-methoxyindolin-2-yl)-1H-indole (1) 10. Compound for use, according to any of the previous claims, wherein the frontotemporal dementia or frontotemporal lobar dementia is characterized by the presence of mutations in the MAPT gene. 11. Compound for use, according to any of the previous claims, wherein the frontotemporal dementia or frontotemporal lobar dementia is selected from the list comprising: Pick's disease, corticobasal degeneration, progressive supranuclear palsy, argyrophilic grain disease, multiple system tauopathy with dementia, neurofibrillary tangle predominant dementia and/or white matter tauopathy with globular glial inclusions. 12. Compound for use, according to any of the previous claims, wherein the frontotemporal dementia or frontotemporal lobar dementia is characterized by the presence of mutation P301L in the MAPT gene. 13. Compound for use, according to any of the previous claims, wherein the compound is administered via parenteral or enteral route, preferably via sublingual, buccal, oral and rectal routes. 14. Compound for use, according to any of the previous claims, wherein the compound is administered via enteral or parenteral route at a concentration ranging from 20 to 100 mg/kg. 15. Pharmaceutical composition comprising the Formula I or Formula II, according to any of the claims 1 to 13, or salts or derivatives thereof, and optionally pharmaceutically acceptable excipients and/or carriers, for use in the treatment of frontotemporal dementia or frontotemporal lobar dementia.

Índice de la ficha

En detalle

Resumen

Reivindicaciones

Etiquetas